Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare Biotechnology

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Hello!

<< Previous

Bullboard Posts

Next >>

Comment by Moonshiner592on Jul 22, 2021 3:42pm

121 Views

Post# 33591262

RE:Hello!

bud13 wrote:
not much happening here yet up or down. So as expected I would think that we will stay right here thru the RS then the shorts will probably make a move first thing in the morning. Unless there's a pretty good nr we'll be drifting. I hope there's a plan as we're going to c very soon. Something big after closing would be great!!

Something big after today's close? ... would be super!!

<< Previous

Bullboard Posts

Next >>

Canada Nickel unveils second of seven resources planned by mid-2025